EXAS News Alert Exact Sciences Corp (EXAS) 26.00 12/04/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 4, 2014 at 6:18 PM

Exact Sciences Corp (EXAS) 26.00 $EXAS

Exact Sciences Announces Mercy Hospital St. Louis Now Offering Cologuard(R)
Business Wire - Tue Dec 02, 7:01AM CST
Exact Sciences Corp. (NASDAQ: EXAS) today announced that Mercy Hospital St. Louis will now offer Cologuard(R), the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Colorectal cancer is the second-leading cancer related cause of death in the United States and is often the most preventable. However, due to the lack of patient compliance with current screening options, it's the least prevented cancer.
EXAS: 26.00 (+0.88)

Reimbursement set for Cologuard
Seeking Alpha - at Seeking Alpha - Tue Nov 25, 12:15PM CST

EXAS: 26.00 (+0.88)

Exact Sciences Announces Final Payment Decision for Cologuard(R) from the Centers for Medicare & Medicaid Services
Business Wire - Tue Nov 25, 11:42AM CST
Exact Sciences Corp. (NASDAQ: EXAS) today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final payment decision regarding Cologuard and will reimburse it at $502 per test. Cologuard is the first and only FDA-approved noninvasive stool DNA colorectal cancer screening test.
EXAS: 26.00 (+0.88)

Jim Cramer's Top Stock Picks: HPQ HOG BC PII ZTS EXAS
at The Street - Sat Nov 22, 5:00AM CST
Cramer says Zoetis is leading the charge on animal health and he sees good things ahead for Exact Sciences.
ZTS: 44.00 (-0.88), HOG: 69.69 (+0.55), BC: 50.36 (+0.37), EXAS: 26.00 (+0.88), HPQ: 39.07 (+0.02), PII: 153.32 (-0.64)

Investment Banker Dick Huebner On How To Uncover Micro-Cap Biotechs That Deliver On Promises
Life Sciences Report - Seeking Alpha - Fri Nov 21, 9:37AM CST
Micro-cap stocks suffer from all sorts of ills. They are often illiquid, and companies can be unable to raise new funds under reasonable terms, if at all. Investing in these equities requires extraordinary expertise and experience, and that is where...
EXAS: 26.00 (+0.88)

Exact Sciences: Caught Between Bulls And Bears
SNJBiostoxx - at Seeking Alpha - Tue Nov 18, 2:38AM CST

VIVO: 16.74 (-0.11), TMO: 128.39 (-0.53), EXAS: 26.00 (+0.88)

Cologuard(R) Wins Popular Science Magazine's 2014 "Best of What's New" Award
Business Wire - Wed Nov 12, 11:30AM CST
Exact Sciences Corp. (NASDAQ: EXAS) today announced Cologuard has received a 2014 "Best of What's New" award from Popular Science.
EXAS: 26.00 (+0.88)

Exact Sciences Earnings In Retrospect: Down 3.3% in the Last 14 Days (EXAS)
Comtex SmarTrend(R) - Mon Nov 10, 1:05PM CST
Two weeks ago on October 27th, 2014 Exact Sciences (NASDAQ:EXAS) reported earnings and analysts, on average, expected a loss of $0.32 on sales of $156.0 thousand. Exact Sciences actually reported a loss of $0.39 per share on sales of $0.0 thousand, missing EPS estimates by $0.07 and matching revenue estimates. Since the company's report, shares of Exact Sciences have fallen from $23.61 to $22.82, representing a loss of 3.3% in the past 14 days.
EXAS: 26.00 (+0.88)

VYCOR: "On the Cusp of the Next Big Healthcare Trend"
ACCESSWIRE - Mon Nov 10, 8:23AM CST
Vycor: "On the Cusp of the Next Big Healthcare Trend"
MDVN: 113.16 (-1.84), ABMD: 35.65 (+0.22), JNJ: 107.56 (-0.16), AMGN: 166.55 (-1.52), EXAS: 26.00 (+0.88), ARAY: 6.90 (+0.16), HOLX: 26.52 (-0.11), PBYI: 195.55 (-2.12)

Technical Pulse on Biotech Stocks - Dendreon, Alkermes, Exact Sciences, Inovio Pharma, and Seattle Genetics
PR Newswire - Mon Nov 10, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Dendreon Corporation (NASDAQ: DNDN), Alkermes PLC (NASDAQ: ALKS), Exact Sciences Corporation (NASDAQ: EXAS), Inovio Pharmaceuticals Inc. (NASDAQ: INO), and Seattle Genetics Inc. (NASDAQ: SGEN). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, November 07, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,573.93, up 0.11% and the NASDAQ Composite closed at 4,632.53, down 0.13%. The S&P 500 finished the session 0.03% higher at 2,031.92. During the trading session, seven out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 775.27, down 0.94%, whereas the index has gained 10.75% in the previous three months. Register for your complimentary reports on these five stocks at:
INO: 8.78 (-0.46), SGEN: 36.50 (-0.91), DNDN: 0.13 (-0.02), EXAS: 26.00 (+0.88), ALKS: 56.71 (-0.33)

MDXHealth - Piggybacking On Exact Sciences' Cologuard Success
SNJBiostoxx - at Seeking Alpha - Thu Nov 06, 10:43AM CST

EXAS: 26.00 (+0.88)

American Cancer Society Includes Exact Sciences' Cologuard in Colorectal Cancer Prevention and Early Detection Guidelines
Business Wire - Thu Nov 06, 7:02AM CST
Exact Sciences Corp. (NASDAQ: EXAS) today announced that the American Cancer Society's Colorectal Cancer Prevention and Early Detection national guidelines for colorectal cancer screening now reflect the commercial availability of Cologuard, the company's noninvasive stool DNA colorectal cancer screening test.
EXAS: 26.00 (+0.88)

Exact Sciences to Participate in November Conferences
Business Wire - Wed Nov 05, 3:31PM CST
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in three investor conferences during November.
EXAS: 26.00 (+0.88)

Using Existing Technology To Anticipate Adoption Of Exact Sciences' Cologuard Test
Doug Van Cuyk - at Seeking Alpha - Tue Nov 04, 12:04PM CST

EXAS: 26.00 (+0.88)

Exact Sciences lowers earnings 187% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 12:08PM CST

EXAS: 26.00 (+0.88)

Exact Sciences: Q3 Marketing Efforts Look Promising
AlphaIdeas - at Seeking Alpha - Wed Oct 29, 4:22PM CDT

EXAS: 26.00 (+0.88)

Exact Sciences Announces Meriter-UnityPoint Health Now Offering Cologuard(R)
Business Wire - Wed Oct 29, 8:00AM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that Meriter-UnityPoint Health will now offer Cologuard(R), the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer.
EXAS: 26.00 (+0.88)

Downgrade Alert for Exact Sciences (EXAS)
Comtex SmarTrend(R) - Tue Oct 28, 7:04AM CDT
Exact Sciences (NASDAQ:EXAS) was downgraded from Overweight to Equal Weight at Stephens today. The stock closed yesterday at $23.61 on volume of 2.4 million shares, below average daily volume of 2.5 million. Exact Sciences (NASDAQ:EXAS) is currently priced 20.7% above its average consensus analyst price target of $18.73. The stock should discover initial support at its 50-day moving average (MA) of $20.89 and subsequent support at its 200-day MA of $15.94.
EXAS: 26.00 (+0.88)

EXACT Sciences' (EXAS) CEO Kevin Conroy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Oct 27, 3:19PM CDT

EXAS: 26.00 (+0.88)

EXACT Sciences (EXAS) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Oct 27, 8:55AM CDT

EXAS: 26.00 (+0.88)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....